BNP Paribas Asset Management
OCUL icon

BNP Paribas Asset Management’s Ocular Therapeutix OCUL Stock Holding History

BNP Paribas Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.15M Sell
423,011
-18,764
-4% -$170K ﹤0.01% 947
2026
Q1 		$3.74M Sell
441,775
-3,630
-0.8% -$34.6K ﹤0.01% 931
2025
Q4 		$5.41M Buy
445,405
+444,414
+44,845% +$5.4M 0.01% 819
2025
Q3 		$12K Hold
991
– – ﹤0.01% 1575
2025
Q2 		$9K Buy
+991
New +$7.76K ﹤0.01% 1816

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BNP Paribas Asset Management's OCUL Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Ocular Therapeutix (OCUL) stake by 4.2% in Q2 2026, selling an estimated $170K and leaving 423,011 shares worth $4.15M. The position accounts for ﹤0.01% of the portfolio, ranked #947.

BNP Paribas Asset Management first reported a position in OCUL in Q2 2025 and has held it in 5 quarters since. The position peaked at $5.41M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • BNP Paribas Asset Management held 423,011 shares of Ocular Therapeutix worth $4.15M as of Q2 2026.
  • BNP Paribas Asset Management sold 18,764 Ocular Therapeutix shares in Q2 2026, an estimated $170K.
  • Ocular Therapeutix made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #947 holding.
  • BNP Paribas Asset Management first reported a position in Ocular Therapeutix in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's Ocular Therapeutix position peaked at $5.41M in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.